Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: GLUE

Monte Rosa Therapeutics, Inc.

Healthcare | Biotechnology

Market prices for GLUE are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 01:50 UTC.

Key facts

Valuation
Return on equity-16.57%

Revenue, margins & earnings

FY2024: net loss $73M on revenue $76M$76MFY2024FY2025: net loss $39M on revenue $124M$124MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-06
  • 2026-10-06Principal Accounting OfficerSale-13$137
  • 2026-07-17President & CEOSale-9,500$220.2K
  • 2026-07-16Chief Operating OfficerOption exercise4,351$17.3K
Sign in to see all transactions →

Company news

View all →

Questions this page answers

What does Monte Rosa Therapeutics, Inc. do?

Monte Rosa Therapeutics, Inc. is a biotechnology company, listed on NASDAQ as GLUE.

When did GLUE last file with the SEC?

Monte Rosa Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-11. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 01:50 UTC. This page is also available as JSON at /api/data?ticker=GLUE and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for GLUE and 5,000+ tickers.

Create a free account — keep GLUE
For your agent
GET /api/data?ticker=GLUE

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt